Kornimate/medical-research-clean huggingface dataset:
post-fracture medication and mortality

Conditions: Osteoporosis; Osteoporosis Fracture; Drug Therapy; Mortality; Adherence, Medication

Summary: osteoporotic fracture is a common public-health problem in the whole world. although postfracture usage of anti-osteoporosis medications, may reduce mortality, recent results have been inconsistent. the investigators aim to examine associations between osteoporosis medication and mortality in older adults and any type of fracture patients. the investigators also aim to discuss the pleiotropic effects of different types of anti-osteoporosis medications.

osteoporotic fracture has become a serious health and economic burden as life expectancy increases. in a who report, the burden of osteoporotic fractures in 2002 was 2.8 million disability-adjusted life years, which is more than that for hypertension and slightly less than that for diabetes mellitus or chronic obstructive pulmonary diseases. many patients who have had a diagnosed fracture have never been diagnosed with osteoporosis, therefore, closing the gap in osteoporosis treatment is important. this situation is primarily due to the fact that osteoporosis symptoms are often not recognized until a fracture occurs. osteoporotic fractures, especially those of the hip and vertebral, are associated with an increased risk of death. early detection of high risk for osteoporotic fractures is important; however, post-fracture management, especially interventions intended to lower mortality, is an emerging public health issue in rapidly aging societies. the burden of osteoporotic fracture is higher than that of hypertension, however, osteoporosis is always given less attention than other chronic diseases by health professionals and the general population.

Eligibility criteria:
inclusion criteria: * newly diagnosed osteoporosis and hip fracture are defined as a claim record from the nhird between 2009 and 2017. exclusion criteria: * patients with a diagnosis of osteoporosis or osteoporotic fractures in 2008 or before were excluded.
nimotuzumab in combination with chemoradiation for nasopharyngeal cancer

Conditions: Nasopharyngeal Cancer

Summary: nimotuzumab is an igg1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (egfr). clinical trials are ongoing globally to evaluate nimotuzumab in different indications. nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (scchn), glioma and nasopharyngeal cancer in different countries. the clinical efficacy has been shown in adult with head and neck cancer. the study assessed the clinical efficacy, and safety of the combination of nimotuzumab administered concomitantly with chemotherapy and radiotherapy in patients with advanced nasopharyngeal cancer.

patients with advanced nasopharyngeal cancer will be randomized to 2 arms. the patients in experimental arm will be treated with nimotuzumab which will be used concurrently with radiotherapy and chemotherapy. the chemotherapy regimen were cisplatin monotherapy. the active comparator arm will be administered chemotherapy and radiotherapy only. the dose and regimen were the same with experiment arm. the patients'hematopoietic , hepatic and renal function tests will be monitored weekly, a physical exam and reassessment of the tumor will be performed at the first and the fourth month, and followup every six months to evaluate the survival index in three years after the study.

Eligibility criteria:
inclusion criteria: * joined the study voluntary and signed informed consent form * age 18-70，both genders. * nasopharyngeal cancer was confirmed by pathology. * nasopharyngeal cancer 2008 stages: ⅲ/ⅳa. * primary lesions can measurable. * karnofsky performance scale \>70. * life expectancy of more than 6 months. * use of an effective contraceptive method for women when there is a risk of pregnancy during the study. * haemoglobin≥100g/l ,wbc ≥4×109/l, platelet count≥100×109/l * hepatic function:alat、asat\< 1.5 x uln, tbil\< 1.5 x uln * renal function: creatinine \< 1.5 x uln exclusion criteria: * evidence of distant metastasis * primary lesions or lymph node have been operated (except of operation for biopsy) * previous radiotherapy * received other anti egfr monoclonal antibody treatment * previous chemotherapy or immunization therapy * other malignant tumor (except of non-melanoma skin cancer or carcinoma in situ of cervix) * participation in other interventional clinical trials within 1 month * peripheral neuropathy is more than i stage * pregnant or breast-feeding women and women who refused to take contraceptive method * history of serious allergic or allergy * history of serious lung or heart disease * refused or can't signed informed consent form * drug abuse or alcohol addiction * personality or psychiatric disease, and persons without capacity for civil conduct or persons with limited capacity for civil conduct

Keywords: nimotuzumab nasopharyngeal cancer chemoradiation
evaluation and standardization of ginseng and it's components for blood pressure regulation

Conditions: Hypertension; Blood Pressure; Endothelial Function

Summary: ginseng has been used for many years in a wide array of anecdotal medicinal properties. animal and limited clinical research points to the vascular effects of korean red ginseng (krg). the present project aims to assess the efficacy of krg and contribution of its factionated components on various indices of vascular function in healthy individuals. our primary objective is to compare the acute effects of krg and placebo on endothelial function. moreover, our secondary objective is to evaluate the effect of isolated krg factions on arterial stiffness, blood pressure and vasoactive markers. we hypothesize that (1) consumption of krg will cause an improvement in endothelial function in healthy individuals, as compared to placebo; (2) consumption of krg will cause an improvement in arterial stiffness and blood pressure in healthy individuals, as compared to placebo; (3) the ginsenoside faction of krg is primarily responsible for the anticipated vascular effects.


Eligibility criteria:
inclusion criteria: * age: between 18 and 70 years of age * healthy individuals (absence of major illnesses) exclusion criteria: * primary hypertension (defined by the use of antihypertensive agents or a seated systolic blood pressure greater than or equal to 140mmhg or diastolic blood pressure greater than 90mmhg) * secondary hypertension (defined as sbp greater than 180mmhg and dbp greater than 110mmhg) * grade 3 hypertension (defined as sbp greater than 180mmhg and dbp greater than 110mmhg) * diabetes * chronic kidney disease * liver disease * estrogen-sensitive cancer * heavy alcohol use * bleeding disorders * planned surgery * angina * chf * coronary revascularization * peripheral vascular disease * coronary/cerebrovascular event in the last 6 months * prescriptions of mao inhibitors, ssris, diuretics, sympathomimetics, herbal therapies, medication affecting nitric oxide synthesis, and/or anticoagulent medications within the last 6 months * sensitivity to any of the ingredients in the treatments or placebo * chronic use of or frequent prescriptions for nsaids * women of childbearing potential must not be pregnant or breast-feeding

Keywords: ginseng korean red ginseng ginsenoside flow mediated dilation endothelial function hypertension
the effect of hydroxychloroquine treatment in hashimoto's thyroiditis

Conditions: Hashimoto Thyroiditis

Summary: hashimoto's thyroiditis is an autoimmune thyroid disease, which induced chronic inflammation of thyroid gland and destroys thyroid tissue. hydroxychloroquine is used as disease modifying anti-rheumatic drug (dmard) for treatment of several autoimmune diseases, such as systemic lupus erythematosus (sle), rheumatoid arthritis(ra) for more than one century. the purpose of this study is to evaluate whether hydroxychloroquine is effective in treatment of hashimoto's thyroiditis.

hashimoto's thyroiditis is an autoimmune thyroid disease, and when the disease progresses, thyroid function finally declined to hypothyroidism. there was no medical treatment recommended for patients with hashimoto's thyroiditis, but currently at euthyroid state. levothyroxine replacement therapy starts if patients become hypothyroid state. hashimoto's thyroiditis is a t-cell mediated autoimmune thyroid disease. the major auto-antigens include thyroid peroxidase (tpo) and thyroglobulin. anti-tpo antibodies induce antibody-dependent cell-mediated cytotoxicity (adcc) and cause destruction of thyroid tissues. antimalarial agents like hydroxychloroquine have several pharmacologic effects which may be involved in the treatment of rheumatic diseases, but the role of each is not known. these include interaction with sulphydryl groups, interference with enzyme activity (including phospholipase, nicotinamide adenine dinucleotide hydrogen-cytochrome c reductase, cholinesterase, proteases and hydrolases), dna binding, stabilisation of lysosome membranes, inhibition of prostaglandin formation, inhibition of polymorphonuclear cell chemotaxis and phagocytosis. this study is to investigate the treatment effect of hydroxychloroquine on autoantibodies and disease progression of hashimoto's thyroiditis.

Eligibility criteria:
inclusion criteria: * hashimoto's thyroiditis * euthyroid state (free t4 and thyroid-stimulating hormone level within normal limit) * never receive immunomodulators or immunosuppressants exclusion criteria: * planned pregnant or already pregnant women * renal insufficiency * hepatic insufficiency * anemia * agranulocytosis * thrombocytopenia * glucose-6-phosphate dehydrogenase deficiency * porphyria cutaneous tarda * allergy to 4-aminoquinolone
study of ak156 in primary osteoporosis patients

Conditions: Osteoporosis

Summary: the purpose of this study is to investigate the efficacy and safety of ak156 in japanese patients with primary osteoporosis.


Eligibility criteria:
inclusion criteria: * patients diagnosed with primary osteoporosis * patients who have vertebral fractures at the time of screening exclusion criteria: * patients diagnosed with secondary osteoporosis * patients with a current uncontrolled medical disorder or other condition which makes the patient unsuitable for the study

Keywords: ak156
the role of kinesiophobia in the functional recovery after hip replacement

Conditions: Hip Osteoarthritis

Summary: several authors explain as the kinesiophobia plays an important role for the recovery after orthopaedic surgery. the aim of the investigators study is to investigate if the kinesiophobia is able to influence the early recovery after total hip arthroplasty. the early recovery will be measured by the iloa score. the tampa scale of kinesiophobia will measure the fear level of movement. all the other variable that could influence the iloa score are identified and collected: age, sex, body max index, ability of patient pre-surgery, type of anesthesia, length of stay, pain, haemoglobin, possible complications.


Eligibility criteria:
inclusion criteria: * primary hip joint replacement * clinical symptoms from more than 3 months exclusion criteria: * other orthopaedic surgery on the lower limb in the last year * not italian speaking * hip arthroplasty following fractures, revision surgery, and partial replacement * patients with concomitant neurologic (parkinson, ictus), rheumatologic (rheumatoid arthritis) diseases, * cognitive impaired.

Keywords: hip replacement, rehabilitation, early ambulation,
management of consecutive exotropia

Conditions: Strabismus; Concomitant Squint; Divergent Strabismus

Summary: patients with consecutive exotropia will be managed by medial rectus muscle advancement +/- resection or medial rectus muscle advancement +/- lateral rectus recession


Eligibility criteria:
inclusion criteria: * patients with consecutive exotropia. * eight years old or more. * cooperative patients. exclusion criteria: * adduction deficit. * mental disability.
the effect of aspirin on recurrent acute pancreatitis

Conditions: Recurrent Acute Pancreatitis; Prevention; Aspirin

Summary: recurrent acute pancreatitis (rap) was defined as two or more occurrences of acute pancreatitis, which was associated with higher percentages of morbidities and mortalities, lower patients' life quality and increased health-care costs. current interventions, including cholecystectomy and abstain from drinking were reported to be effective methods for preventing the recurrences of biliary and alcoholic etiologies, respectively. however, there were no effective preventions for other etiologies, such as idiopathic etiologies. non-steroid anti-inflammatory drugs (nsaids), including indomethacin, diclofenac and aspirin could inhibiting the inflammatory cascade of pancreatitis. in this study, we aimed at exploring the effects of 100mg aspirin on reducing the occurrences of recurrent acute pancreatitis.


Eligibility criteria:
inclusion criteria: * patients with with recurrent acute pancreatitis exclusion criteria: * less than 2 episodes of acute pancreatitis in the past year * latrogenic ap (pancreatitis due to endoscopic retrograde cholangiopancreatography, surgery, or after other invasive treatment). iatrogenic pancreatitis will not count as an episode of recurrent pancreatitis * previous allergy to non-steroid anti-inflammatory drugs (nsaids) * regularly taking aspirin or other nsaids \>3 doses per week * contradictions for the medications of nsaids, including active peptic ulcer disease or gastrointestinal hemorrhage within 3 months or previous peptic ulcer, history of significant hepatic or renal disease, platelet count less than 100x10\^9/l or international normalized ratio (inr) \>1.5) * biliary stones * receiving endoscopic sphincterotomy and/or pancreatic stent placement and/or cholecystectomy and/or pancreatic surgery after the latest pancreatitis or planning to undergo one of those interventions within preceding 2 years * patients with the level of serum triglycerides of \>5.65 mmol/l and did not receive regular lipid-lowering therapy * primary hyperparathyroidism has been well-treated after last episode of pancreatitis and recruitment or will be operated in \<2 years * patients with previously heavy alcohol consumption (50g/day for men, 40g/day for women) and have not quit drinking, or have significant withdrawal symptoms * pregnant or breastfeeding patients * inability to give informed consents
ulinastatin in severe acute pancreatitis

Conditions: Pancreatitis

Summary: this study aims to evaluate the effect of ulinastatin in the treatment and prevention of organ failure in severe acute pancreatitis.

about 20% of patients with acute pancreatitis have a severe course, and 10-15% of those with severe acute pancreatitis (sap) die. despite improvements in intensive care treatment during past few decades, effective therapies for acute pancreatitis are still limited. early deaths (within the first week) due to severe acute pancreatitis are generally caused by massive inflammatory responses which result in multiple organ failure. although the exact mechanisms which trigger the inflammatory processes are not completely understood, it is generally accepted that autodigestion and activated leukocytes play important roles in the pathogenesis of acute pancreatitis. activation of digestive enzymes causes pancreatic injury and results in an inflammatory response that is out of proportion to the response of other organs to a similar insult. the acute inflammatory response itself causes substantial tissue damage and may progress beyond the pancreas to a systemic inflammatory response syndrome, multi organ failure, or death. uti is a multivalent kunitz-type serine protease inhibitor that is found in human urine and blood, it can stabilize lysosome membrane and inhibit lysosome function, inhibit the various enzymes and inflammatory response. previous study proved that it protects against sirs pathophysiology and subsequent organ damage induced via the modulation of the proinflammatory mediator, as well as chemokines. uti has been widely used for the treatment and prevention of multiple organ failure in china, but there is few randomized, placebo controlled trial on ulinastatin. a large multicenter, randomized study is warranted. in this study, we aim to evaluate the effect of ulinastatin in the treatment and prevention of organ failure in severe acute pancreatitis with regular treatment in an add-on trial.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of severe acute pancreatitis , severe acute pancreatitis adapted from the atlanta classification: early prognostic signs: ramson signs ≥3, apache ii score ≥8 organ failure and/or local complications: necrosis, abscess, pseudocyst; * admission within 72h after onset of symptoms of pancreatitis * 18-70 years old * signed the informed consent form exclusion criteria: * pre-existing chronic renal insufficiency requiring hemodialysis or peritoneal dialysis * pre existing heart dysfunction or nyha classification score above iii * pregnancy or lactation * allergy for ulinastatin * received an investigational drug or device within 90 days prior to entering study * serious mentally-ill patients including dementia * on the verge of death (estimated to be mortal in 12h).

Keywords: ulinastatin severe acute pancreatitis
breast study to learn more about the application of optical transillumination measurements to assess breast cancer risk and to potentially detect the presence of breast cancer.

Conditions: Breast Cancer

Summary: this study aims to evaluate if a light based technique, called transillumination breast spectroscopy (tibs), can be used to construct a non-invasive breast cancer risk predictor which provides a better odds ratio than mammographic parenchymal density.

in a previous cross sectional study in a group of women without breast cancer and with varying degrees of parenchymal density patterns, a strong association was demonstrated between transillumination breast spectroscopy (tibs) and x-ray derived mammographic density. from this, we expect that tibs should also provide a comparable odds ratio (4-6) as mammographic density for breast cancer risk shown in other independent epidemiological studies. it is possible that tibs may provide complementary information and a higher odds ratio if compared to the incidence of breast cancer. in contrast to mammography derived parenchymal density pattern, no historical tibs data is available for a retrospective analysis and hence a cross sectional study within a group of screened women is proposed. we hypothesize that tibs provides physical information about the breast tissue which can be used to construct a breast cancer risk predictor with an odd ratio \> 6.

Eligibility criteria:
inclusion criteria: * are in good health and capable of providing consent * are willing to come in to the princess margaret hospital for a single visit to meet with a female research assistant exclusion criteria: * have had breast augmentation or reduction * have a personal history of breast cancer * have had a previous bilateral fine needle aspiration or core biopsy * have a breast tattoo

Keywords: breast cancer risk optical transillumination spectroscopy transillumination breast spectroscopy
proton beam therapy for unresectable liver metastasis

Conditions: Local Control Rate; Side Effect

Summary: the investigators performed the present study to evaluate the role of proton beam therapy for liver metastasis which is unresectable and unsuitable for radiofrequency ablation (rfa) in terms of local control and safety.


Eligibility criteria:
inclusion criteria: * pathologically diagnosed cancer patient * confirmed liver metastasis via computed tomography (ct) or magnetic resonance imaging (mri) or biopsy * unresectable or unsuitable for rfa * solitary liver metastasis or less than 3 metastatic lesions if the distance is less than 3 cm between metastatic lesions * case discussed by surgeon, radiologist, and radiation oncologist * eastern cooperative oncology group performance status 0 to 2 * optimal liver and renal function (child-pugh score 10 or less) * informed consent * agree to be contraceptive for the duration of the study and for the next 6 months exclusion criteria: * uncontrolled ascites or hepatorenal syndrome * status of pregnancy or breast-feeding * less than 12 weeks of expected survival * combined disease known to have high radiation side effects * serious acute illness that is not treated other than liver disease
ofdi-quantified intracoronary thrombus, antiplatelet pretreatment effect and myocardial reperfusion

Conditions: Myocardial Infarction; Thrombosis, Coronary

Summary: the management of st-elevation myocardial infarction in the acute phase requires an optimal antiaggregation combining aspirin and a p2y12 inhibitor (clopidogrel, prasugrel or ticagrelor). primary percutaneous coronary intervention must be performed within 2 hours of first medical contact. however, even with the new p2y12 inhibitors, effective platelet inhibition which is required to inhibit the progression of intracoronary thrombus, is present only in half of the patients at 2 hours. optical coherence tomography (oct) is the reference method for visualizing and quantifying intracoronary thrombus. the post-stenting intracoronary residual mass evaluated in oct was associated with altered myocardial reperfusion indices, which were themselves associated with the prognosis of the patient. however, the determinants of this post-stenting residual mass -mostly thrombotic- remain unknown. measurement of platelet reactivity (expressed as p2y12 reaction unit and aspirin reaction unit) by simple turbidimetric tests (verifynow) is available in the cathlab. enhanced platelet reactivity is reported in patients with acute coronary syndrome and represents a high-risk situation for recurrent coronary events in this setting. the study aims to: 1. to evaluate the relationship between the post-stenting residual intracoronary mass evaluated in oct and the platelet response at the time of the pci evaluated by verify now 2. to confirm the impact of the residual mass measured by oct on the ekg and angiographic myocardial reperfusion indices 3. identify patients with high thrombotic risk who may require more intensive antithrombotic therapy 4. identify simple biological markers associated with the residual mass measured by oct


Eligibility criteria:
inclusion criteria: * primary pci with successful stenting for st-elevation myocardial infarction * pretreated with ticagrelor, aspirin and enoxaparin * oct and verifynow performed in the acute phase exclusion criteria: * stent thrombosis * known coagulation disorder * clinical instability * pregnancy

Keywords: myocardial infarction optical coherence tomography intracoronary thrombus verifynow